BioCentury | Jul 27, 2015
Company News

Omeros, Fagron deal

...Omeros granted Fagron exclusive rights to commercialize OMS103 in the U.S. Fagron will pay Omeros a...
...commence sales this year while bearing sales and marketing costs and meeting annual sales minimums. OMS103...
BioCentury | Jan 7, 2013
Clinical News

OMS103HP: Phase III data

...double-blind, U.S. Phase III trial in 344 patients undergoing arthroscopic partial meniscectomy surgery showed that OMS103HP...
...baseline in the Symptoms Subscale of the KOOS at day 30 vs. vehicle irrigation solution. OMS103HP...
...reducing post-operative pain as measured by a VAS vs. vehicle (p=0.0003). Omeros also said that OMS103HP...
BioCentury | Jan 7, 2013
Finance

4Q Stock Wrap-Up: Go big or go home

...the European Phase IIb ARGO trial to treat mild to moderate AD Omeros Corp. (NASDAQ:OMER) OMS103HP...
BioCentury | Jan 7, 2013
Finance

Highlights of weekly biotech stock moves

...begin this quarter. Omeros Corp. (NASDAQ:OMER) was off $0.88 (14%) to $5.32 Christmas week after OMS103HP...
...improve post-operative joint function and to reduce pain following arthroscopic partial meniscectomy surgery (see B22). OMS103HP...
BioCentury | Dec 28, 2012
Top Story

OMS103HP misses Phase III endpoint

...Omeros Corp. (NASDAQ:OMER) said OMS103HP missed the primary endpoint of improving knee symptoms from baseline to...
...product to improve post-operative joint function and to reduce pain following arthroscopic partial meniscectomy surgery. OMS103HP...
...The double-blind, U.S. trial enrolled 344 patients. Omeros said a second Phase III trial of OMS103HP...
BioCentury | Oct 1, 2012
Finance

3Q Stock Wrap-Up: Back in black

...NASDAQ:NYMX)/Recordati S.p.A. (Milan:REC) NX-1207 Benign prostatic hyperplasia (BPH) Ph III data YE12 Omeros Corp. (NASDAQ:OMER) OMS103HP...
BioCentury | Aug 13, 2012
Clinical News

OMS103HP: Completed Phase III enrollment

...Omeros completed enrollment in a double-blind, placebo-controlled Phase III trial evaluating OMS103HP in about 330 patients...
...of the product in patients undergoing arthroscopic anterior cruciate ligament (ACL) reconstruction surgery, for which OMS103HP...
...in Phase III testing (see BioCentury, April 4, 2011). Omeros Corp. (NASDAQ:OMER), Seattle, Wash. Product: OMS103HP...
BioCentury | Jul 2, 2012
Finance

3Q Financial Markets Preview: Miles of milestones

...Tokyo:4502) Natpara recombinant human parathyroid hormone 1-84 (PTH) Hypoparathyroidism Submit BLA 1H12 Omeros Corp. (NASDAQ:OMER) OMS103HP...
BioCentury | Jan 9, 2012
Finance

PDUFAs produce yawns

Stephen Hansen Senior Writer There are more than twice as many PDUFA dates this year than last - at least 40 vs. 17 - but only a handful of potential approvals are drumming up interest among buysiders....
BioCentury | Dec 12, 2011
Analyst Picks & Changes

Analyst picks & changes

...said he is "optimistic" about data anticipated in mid-2012 from a Phase III trial of OMS103HP...
...OMS302 is a combination of an undisclosed anti-inflammatory agent and a pupil dilation agent, and OMS103HP...
Items per page:
1 - 10 of 38